Vinorelbine
Malignant Testicular Neoplasm
National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Malignant Testicular Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
Carboplatin National Cancer Institute (NCI) | Phase 1 | CC |
Veliparib National Cancer Institute (NCI) | Phase 1 | CC |
FAPi-46 Jonsson Comprehensive Cancer Center | Phase 1 | CC |
FLUDEOXYGLUCOSE Jonsson Comprehensive Cancer Center | Phase 1 | CC |
BLOOD, WHOLE Mayo Clinic | D |
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →